Corvus Pharmaceuticals Inc (CRVS) — Cash Flow-to-Debt Ratio
Corvus Pharmaceuticals Inc (CRVS) has a Cash Flow-to-Debt Ratio of -0.93x as of December 2025, meaning its operating cash flow of $-9.19 Million could theoretically repay -1% of its total liabilities ($9.91 Million) in one year. See working capital to net assets of Corvus Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Corvus Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Corvus Pharmaceuticals Inc across 12 annual periods. Also explore how fast is Corvus Pharmaceuticals Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Corvus Pharmaceuticals Inc (2014–2025)
Year-by-year debt coverage analysis for Corvus Pharmaceuticals Inc. For market capitalisation and broader financial context, see CRVS market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.31x | $-32.80 Million | $9.91 Million | ▼ -372.8% |
| 2024 | -0.70x | $-25.42 Million | $36.34 Million | ▲ +79.9% |
| 2023 | -3.48x | $-23.93 Million | $6.87 Million | ▼ -56.3% |
| 2022 | -2.23x | $-27.02 Million | $12.12 Million | ▲ +25.4% |
| 2021 | -2.99x | $-36.72 Million | $12.29 Million | ▼ -14.9% |
| 2020 | -2.60x | $-34.78 Million | $13.38 Million | ▲ +12.7% |
| 2019 | -2.98x | $-37.32 Million | $12.54 Million | ▲ +42.6% |
| 2018 | -5.19x | $-40.99 Million | $7.90 Million | ▼ -11.7% |
| 2017 | -4.65x | $-46.21 Million | $9.94 Million | ▼ -22.6% |
| 2016 | -3.79x | $-27.86 Million | $7.35 Million | ▼ -4235.3% |
| 2015 | -0.09x | $-11.33 Million | $129.56 Million | ▼ -959.3% |
| 2014 | -0.01x | $-104.73K | $12.69 Million | — |